SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 10/1/2016 4:25:11 AM - Followers: 838 - Board type: Free - Posts Today: 1

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Current Report Filing (8-k) 09/01/2016 04:32:35 PM
ELTP News: Current Report Filing (8-k) 08/31/2016 04:19:33 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 08/19/2016 05:48:03 PM
ELTP News: Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements 07/27/2016 09:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/21/2016 11:47:37 AM
PostSubject
#226048  Sticky Note Elite Pharmaceuticals (ELTP) is NOT a Religion !! IB_ 09/05/16 12:28:35 PM
#226023  Sticky Note Concerning the Warning Letter for those interested in Minding 09/05/16 11:37:37 AM
#225095  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 08/31/16 08:53:18 AM
#222196  Sticky Note Freedom of Information Act Request to FDA WeeZuhl 08/17/16 07:21:46 AM
#217429  Sticky Note Here is the TRUTH about T-max-SEC-Filed! Drugdoctor 07/25/16 06:43:08 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#228718   Earnings report in 40 days. aELmTPa 10/01/16 04:25:10 AM
#228717   Could you please tell me which MM's are John_Langston 09/30/16 11:21:47 PM
#228716   Real Inquiry... PH4RM4C3UT1C4LS 09/30/16 10:57:30 PM
#228715   I don't know about $38 but we we're stockboy 09/30/16 10:13:08 PM
#228714   Better rethink positions in ELTP.. Holders are taking namtae 09/30/16 09:37:29 PM
#228713   Nice to dream isn't it? 2016 LOL stockboy 09/30/16 08:56:05 PM
#228712   I know July 2016; which reminds me I John_Langston 09/30/16 08:47:41 PM
#228711   2016 What year do you see SequesTOX being approved aELmTPa 09/30/16 08:43:30 PM
#228710   Another I heard that BS at .06 cents. Couch 09/30/16 08:20:22 PM
#228709   The ones who ran it to .97. Couch 09/30/16 08:19:29 PM
#228708   I could see 2 billion easy but 4 John_Langston 09/30/16 08:18:34 PM
#228707   No doubt I will hear it again at $2. Couch 09/30/16 08:17:50 PM
#228706   Who said that in 2011? John_Langston 09/30/16 08:16:20 PM
#228705   No doubt I will hear it again at 6¢. John_Langston 09/30/16 08:14:56 PM
#228704   That's the one that will always find buyers Couch 09/30/16 08:14:12 PM
#228703   I see a buyout after a few ADFs John_Langston 09/30/16 08:13:40 PM
#228702   and working on John_Langston 09/30/16 08:12:06 PM
#228701   But but but I was told .02 cent Couch 09/30/16 08:11:44 PM
#228700   But those shares were bought in 2014 not 2013. John_Langston 09/30/16 08:10:05 PM
#228699   I heard the same BS at .06 cents. Couch 09/30/16 08:05:23 PM
#228698   That was the strong non-retail MM bid support. John_Langston 09/30/16 08:04:16 PM
#228697   What year do you see SequesTOX being approved stockboy 09/30/16 08:01:23 PM
#228696   I see a buyout after a few ADFs approved. NASDAQ2020 09/30/16 07:48:03 PM
#228695   Gee so that explains why the PPS closed Couch 09/30/16 07:46:52 PM
#228694   Gee you mean besides file the generic Eli Couch 09/30/16 07:46:03 PM
#228693   ELTP is up 175% since 2013. Couch 09/30/16 07:44:29 PM
#228692   All those "sellers" must be why it closed Couch 09/30/16 07:42:53 PM
#228691   That doesn't even make sense on July 18th stockboy 09/30/16 07:29:41 PM
#228690   About the same thing as up 50% since John_Langston 09/30/16 07:22:19 PM
#228689   Third, SequestOx. Adjacently the requirements are underway. On NASDAQ2020 09/30/16 07:22:05 PM
#228688   Soooooooooo toybaby 09/30/16 07:12:04 PM
#228687   Massive buying 520k SHARES LMAO... REALLY 520k is stockboy 09/30/16 07:11:12 PM
#228686   That's all well and good, has nothing to stockboy 09/30/16 07:02:16 PM
#228685   ELTP is down 50% from 2014. John_Langston 09/30/16 06:49:12 PM
#228683   Another seller day; I mean stellar day for John_Langston 09/30/16 06:09:20 PM
#228682   There is absolutely positively nothing wrong with ELTP. Dr PeteRose MLB 09/30/16 06:04:17 PM
#228681   Looks like ELTP is breaking wide open! JJAAMMAANN 09/30/16 05:58:05 PM
#228680   Yup the asian boys are buying YJ4LIFE 09/30/16 04:58:15 PM
#228679   Bluesummers- agree 1000%, thanks for your perspective. It littlerhody 09/30/16 04:25:07 PM
#228678   I'm happy. Higher than it was when I steve9465 09/30/16 04:20:20 PM
#228677   Lasers, it is a start, The seller that took snupoled 09/30/16 04:02:58 PM
#228676   Lol this is great. 10k shares on BostonTrader 09/30/16 03:57:35 PM
#228675   Why I believe Anti-abuse drugs will become the Bluesummers 09/30/16 03:34:13 PM
#228674   $ELTP new HOD $0.1825! lasers 09/30/16 03:21:58 PM
#228673   corpus, finger gently brushing nostril, nod of approval snupoled 09/30/16 03:12:07 PM
#228672   That's exactly why im adding here. NASDAQ2020 09/30/16 03:08:38 PM
#228671   Im watching for GREAT news, SequestOx NASDAQ2020 09/30/16 03:05:13 PM
#228670   Both statements are equally possible. Couch 09/30/16 02:40:38 PM
#228668   Both statements are equally possible. I'm not sure why joseytheoutlawwales 09/30/16 02:05:12 PM
#228667   Back when Elite was at $0.04 what would IB_ 09/30/16 02:02:58 PM
PostSubject